Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$27,000.00
Unveiling the Interplay of DPP4 and EPDR1 in Obesity: Implications for Type 2 Diabetes and Atherosclerosis
FY 2024-25
Summary
Obesity, marked by the accumulation of excessive white fat tissue, is a major risk factor for type 2 diabetes (T2D) and heart disease, which can lead to heart attacks and strokes. This research explores how obesity accelerates T2D and the development of fat-rich blockages in the arteries (called atherosclerosis), focusing on a protein called dipeptidyl peptidase 4 (DPP4) and another protein it affects, mammalian ependymin-related protein 1 (EPDR1). DPP4 acts like molecular scissors to cut and inactivate certain hormones, like glucagon-like peptide 1 (GLP-1), which helps the body regulate blood sugar levels by boosting insulin release from the pancreas. Medications that prevent cutting of GLP-1 by DPP4 to enhance GLP-1's activity are already used to treat T2D and obesity. Therefore, targeting another protein inactivated by DPP4 to better treat T2D and heart disease holds promise. EPDR1, a protein produced by fat and immune cells, is linked to regulating metabolism of fats and the development of energy-rich brown fat tissue that burns calories to generate heat. Interestingly, EPDR1 levels are elevated in individuals with T2D and heart disease, suggesting it plays a role in these conditions. We hypothesize that in obesity, DPP4 cuts EPDR1, inactivating it, and therefore contributing to the progression of diabetes and heart disease. To test this, we will examine how EPDR1 affects blood sugar control and fat metabolism by using cells and mice fed a high-fat diet supplemented with EPDR1 protein. To add, we will investigate how EPDR1 impacts the inflammatory status of immune cells and the buildup of blockages in arteries. This study hopes to advance the creation of innovative treatments targeting DPP4 and EPDR1 to combat obesity-related diabetes and heart disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530299
Name
Abdalbari Ali A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Unveiling the Interplay of DPP4 and EPDR1 in Obesity: Implications for Type 2 Diabetes and Atherosclerosis
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adipose Tissue; Atherosclerosis; Dipeptidyl Peptidase 4 (Dpp4); Ependymin Related Protein 1 (Epdr1); Glucose And Lipid Metabolism; Heart Disease; Inflammation; Macrophage Polarization; Obesity; Type 2 Diabetes
Abstract
Obesity, marked by the accumulation of excessive white fat tissue, is a major risk factor for type 2 diabetes (T2D) and heart disease, which can lead to heart attacks and strokes. This research explores how obesity accelerates T2D and the development of fat-rich blockages in the arteries (called atherosclerosis), focusing on a protein called dipeptidyl peptidase 4 (DPP4) and another protein it affects, mammalian ependymin-related protein 1 (EPDR1). DPP4 acts like molecular scissors to cut and inactivate certain hormones, like glucagon-like peptide 1 (GLP-1), which helps the body regulate blood sugar levels by boosting insulin release from the pancreas. Medications that prevent cutting of GLP-1 by DPP4 to enhance GLP-1's activity are already used to treat T2D and obesity. Therefore, targeting another protein inactivated by DPP4 to better treat T2D and heart disease holds promise. EPDR1, a protein produced by fat and immune cells, is linked to regulating metabolism of fats and the development of energy-rich brown fat tissue that burns calories to generate heat. Interestingly, EPDR1 levels are elevated in individuals with T2D and heart disease, suggesting it plays a role in these conditions. We hypothesize that in obesity, DPP4 cuts EPDR1, inactivating it, and therefore contributing to the progression of diabetes and heart disease. To test this, we will examine how EPDR1 affects blood sugar control and fat metabolism by using cells and mice fed a high-fat diet supplemented with EPDR1 protein. To add, we will investigate how EPDR1 impacts the inflammatory status of immune cells and the buildup of blockages in arteries. This study hopes to advance the creation of innovative treatments targeting DPP4 and EPDR1 to combat obesity-related diabetes and heart disease.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Abdalbari, Ali A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~